Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022
Ivan Foeldvari(Center for Rheumatology), Daniel F. Furst(University of California, Los Angeles), Jordi Antón, Kim Fligelstone(Scleroderma and Raynaud's UK), Bernd Hinrichs(Asklepios Fachklinikum Brandenburg), Vanessa Smith(Lund University), Pia Moinzadeh(University of Cologne), Clare Pain(University of Toronto), Suzanne C. Li(Hackensack Meridian Health), Edoardo Marrani(Meyer Children's Hospital), John D Pauling(Royal National Hospital for Rheumatic Diseases), Catherine H. Orteu(Royal Free London NHS Foundation Trust), Clarissa Pilkington, Franziska Rosser, Tamás Constantin, Susan Maillard, Maurizio Cutolo, Michael Blakley(Indiana University Health), Christopher P Denton, Kathryn S. Torok(University of Pittsburgh Medical Center)
UCL Discovery (University College London)
January 1, 2024
Cited by 0
Related Papers
Long-term Psychological and Occupational Effects of Providing Hospital Healthcare during SARS Outbreak
|Emerging infectious diseases|2006|1.2k
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
|Arthritis & Rheumatology|2014|430
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement
|Lara D. Veeken|2008|287
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|262